Actuate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	16.92	8.64	2.96	20.45
Cash & Short-Term Investments	16.92	8.64	2.96	20.45
Cash Growth	25.15%	192.08%	-85.53%	-
Prepaid Expenses	0.52	0.57	0.04	0.03
Total Current Assets	17.44	9.21	3	20.48
Other Long-Term Assets	-	0.11	-	-
Total Assets	17.71	9.32	3	20.48
Accounts Payable	1.25	1.92	3.42	2.13
Accrued Expenses	5.13	6.88	3.5	2.21
Total Current Liabilities	6.37	8.8	6.92	4.34
Other Long-Term Liabilities	0.4	0.41	0.54	0.49
Total Liabilities	6.78	9.21	7.46	4.84
Common Stock	0	0	0	0
Additional Paid-In Capital	160.99	132.48	5.47	5.04
Retained Earnings	-150.05	-132.38	-105.09	-80.35
Total Common Equity	10.94	0.1	-99.63	-75.31
Shareholders' Equity	10.94	0.1	-4.46	15.65
Total Liabilities & Equity	17.71	9.32	3	20.48
Net Cash (Debt)	16.92	8.64	2.96	20.45
Net Cash Growth	25.15%	192.08%	-85.53%	-
Net Cash Per Share	0.85	1.03	2.06	16.89
Filing Date Shares Outstanding	23.24	19.53	1.69	1.21
Total Common Shares Outstanding	23.24	19.53	1.69	1.21
Working Capital	11.07	0.41	-3.93	16.14
Book Value Per Share	0.47	0.01	-58.93	-62.21
Tangible Book Value	10.94	0.1	-99.63	-75.31
Tangible Book Value Per Share	0.47	0.01	-58.93	-62.21

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q